Mylan reaches $8m settlement with Connecticut over EpiPen prices
( October 22, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Mylan has agreed to pay $8 million to resolve concerns brought by the Connecticut Attorney General over allegations that the company illegally inflated prices for EpiPens in violation of state antitrust and consumer protection laws, the attorney general announced. “Mylan abused its monopoly to jack up prices on its lifesaving, emergency medication. Families were crushed with massive costs while Mylan reaped exorbitant profits. This was corporate greed at its worst, and we’re holding Mylan accountable,” Attorney General William Tong said.Statement follows in full. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.